Drug Profile
INCB 9471
Alternative Names: INCB009471; INCB9471Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antivirals
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 17 Mar 2008 INCB 9471 is available for licensing (http://www.incyte.com)
- 17 Mar 2008 Incyte decides not to initiate phase IIb trials of INCB 9471 in treatment-experienced patients with HIV
- 06 Feb 2008 Pharmacodynamics data from a phase II monotherapy trial presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)